Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.

Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, Knudsen KE, Rui H, Butt T, Diehl JA, McMahon SB.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9298-E9307. doi: 10.1073/pnas.1807704115. Epub 2018 Sep 17.

2.

Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling.

Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H.

Clin Cancer Res. 2018 Aug 10. doi: 10.1158/1078-0432.CCR-17-3280. [Epub ahead of print]

PMID:
30097435
3.

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.

Cancer Res. 2018 Apr 1;78(7):1657-1671. doi: 10.1158/0008-5472.CAN-17-0915. Epub 2018 Jan 22.

PMID:
29358169
4.

Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth.

Pestell TG, Jiao X, Kumar M, Peck AR, Prisco M, Deng S, Li Z, Ertel A, Casimiro MC, Ju X, Di Rocco A, Di Sante G, Katiyar S, Shupp A, Lisanti MP, Jain P, Wu K, Rui H, Hooper DC, Yu Z, Goldman AR, Speicher DW, Laury-Kleintop L, Pestell RG.

Oncotarget. 2017 Aug 4;8(47):81754-81775. doi: 10.18632/oncotarget.19953. eCollection 2017 Oct 10.

5.

Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H, Fuchs SY.

Cancer Cell. 2017 Feb 13;31(2):194-207. doi: 10.1016/j.ccell.2017.01.004.

6.

Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms.

Peck AR, Girondo MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Freydin B, Hyslop T, Chervoneva I, Rui H.

Mod Pathol. 2016 Oct;29(10):1143-54. doi: 10.1038/modpathol.2016.112. Epub 2016 Jun 17.

7.

Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.

Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H.

Oncogene. 2016 Mar 17;35(11):1373-85. doi: 10.1038/onc.2015.193. Epub 2015 Jun 22.

8.

Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment.

Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H.

Breast Cancer Res. 2013;15(5):R73.

9.

Global profiling of prolactin-modulated transcripts in breast cancer in vivo.

Sato T, Tran TH, Peck AR, Liu C, Ertel A, Lin J, Neilson LM, Rui H.

Mol Cancer. 2013 Jun 12;12:59. doi: 10.1186/1476-4598-12-59.

10.

Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.

Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H.

Oncogene. 2014 Apr 24;33(17):2215-24. doi: 10.1038/onc.2013.172. Epub 2013 May 27.

11.

Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes.

Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH, Girondo MA, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, Rimm DL, Magliocco AM, Hyslop T, Rui H.

Breast Cancer Res. 2012 Oct 4;14(5):R130. doi: 10.1186/bcr3328.

12.

Signal transducer and activator of transcription-3 and breast cancer prognosis.

Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz A, Hyslop T, Nevalainen MT, Sauter G, Rui H.

Am J Cancer Res. 2011;1(3):347-55.

13.

Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.

Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H.

J Clin Oncol. 2011 Jun 20;29(18):2448-58. doi: 10.1200/JCO.2010.30.3552. Epub 2011 May 16.

14.

Differential expression of arrestins is a predictor of breast cancer progression and survival.

Michal AM, Peck AR, Tran TH, Liu C, Rimm DL, Rui H, Benovic JL.

Breast Cancer Res Treat. 2011 Dec;130(3):791-807. doi: 10.1007/s10549-011-1374-9. Epub 2011 Feb 12.

15.

PTP1B suppresses prolactin activation of Stat5 in breast cancer cells.

Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H.

Am J Pathol. 2010 Dec;177(6):2971-83. doi: 10.2353/ajpath.2010.090399. Epub 2010 Oct 15.

Supplemental Content

Support Center